Trial Profile
Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2017
Price :
$35
*
At a glance
- Drugs Cendakimab (Primary) ; Cendakimab (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Abbott Laboratories; AbbVie
- 28 Apr 2017 Results published in the Advances in Therapy
- 12 Apr 2011 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 17 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.